organization · Reporting owner

Valor IV Pharma Holdings, LLC

Disclosed activity across 1 company

Tapewire entity: 75909
SEC CIK: 0001821186

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Harmony Biosciences Holdings, Inc.HRMY · Entity 4381	10% owner	August 28, 2025	September 02, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Harmony Biosciences Holdings, Inc.

Report date August 28, 2025 · Filed September 02, 2025

Jointly reported with Valor Management L.P., Valor Equity Capital IV LLC, Valor Equity Associates IV L.P., VALOR EQUITY PARTNERS IV L.P., VALOR EQUITY PARTNERS IV-A L.P., VALOR EQUITY PARTNERS IV-B L.P., Gracias Antonio J., Sabater Juan A.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-08-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-08-28 · Other · Disposed 6,618,033 · Balance 0 F1: In-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	29,497	Reported balance Holding disclosure · report date 2025-08-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 29,497 F2: Shares received in distribution described in footnote 1. F3: Held by Valor Management L.P.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	437,619	Reported balance Holding disclosure · report date 2025-08-28 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 437,619 F2: Shares received in distribution described in footnote 1. F4: Held by Antonio Gracias.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	50,423	Reported balance Holding disclosure · report date 2025-08-28 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 50,423 F2: Shares received in distribution described in footnote 1. F5: Held by AJG Growth Fund LLC, an entity controlled by Mr. Gracias.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	38,275	Reported balance Holding disclosure · report date 2025-08-28 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 38,275 F2: Shares received in distribution described in footnote 1. F6: Held by Juan Sabater.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	23,714	Reported balance Holding disclosure · report date 2025-08-28 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 23,714 F2: Shares received in distribution described in footnote 1. F7: Held by Tamal, LLC, an entity controlled by Mr. Sabater.

Filing footnotes · ownership attribution and instrument terms

F1: In-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration.

F2: Shares received in distribution described in footnote 1.

F3: Held by Valor Management L.P.

F4: Held by Antonio Gracias.

F5: Held by AJG Growth Fund LLC, an entity controlled by Mr. Gracias.

F6: Held by Juan Sabater.

F7: Held by Tamal, LLC, an entity controlled by Mr. Sabater.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 28, 2025 Filed Sep 2, 2025 21:45 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	OtherCommon Stock	6,618,033	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-25-083535 · ownership.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: In-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. F1 · price: In-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. Read SEC document
November 05, 2024 Filed Nov 5, 2024 22:48 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	SaleCommon Stock	600,000	$30.30	$18,181,500.00	Disclosure SEC source: 0001213900-24-094654 · ownership.xml · nonDerivative · entry 2 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,618,033 Read SEC document
November 01, 2024 Filed Nov 5, 2024 22:48 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	SaleCommon Stock	4,000,000	$30.30	$121,210,000.00	Disclosure SEC source: 0001213900-24-094654 · ownership.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,218,033 Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:41 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionSeries C Preferred Stock · Derivative	1,810,126	$0.00	$0.00	Disclosure SEC source: 0000899243-20-023393 · doc4.xml · derivative · entry 4 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F4 · shares: Includes 23,141 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F4 · derivative.underlying_shares: Includes 23,141 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:41 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionSeries A Preferred Stock · Derivative	77,950,712	$0.00	$0.00	Disclosure SEC source: 0000899243-20-023393 · doc4.xml · derivative · entry 3 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,080,352 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F3 · shares: Includes 2,950,712 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F3 · derivative.underlying_shares: Includes 2,950,712 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:41 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionCommon Stock	240,668	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-023393 · doc4.xml · nonDerivative · entry 2 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,166,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Aug 25, 2020 23:41 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionCommon Stock	12,080,352	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-023393 · doc4.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,925,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionSeries C Preferred Stock · Derivative	1,786,985	$0.00	$0.00	Disclosure SEC source: 0000899243-20-024369 · doc4a.xml · derivative · entry 4 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 233,052.23 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F4 · derivative.underlying_shares: Includes 15,525.15 shares of common stock received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionSeries A Preferred Stock · Derivative	75,000,000	$0.00	$0.00	Disclosure SEC source: 0000899243-20-024369 · doc4a.xml · derivative · entry 3 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,139,645.04 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F3 · derivative.underlying_shares: Includes 1,010,004.14 shares of common stock received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionCommon Stock	233,052	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-024369 · doc4a.xml · nonDerivative · entry 2 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,218,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document
August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	ConversionCommon Stock	10,139,645	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-024369 · doc4a.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,984,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.